New hope for rare lung scarring? small trial tests pirfenidone
NCT ID NCT03385668
First seen Nov 20, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This small pilot study looked at whether the drug pirfenidone is safe and effective for people with a specific type of lung scarring (pulmonary fibrosis) linked to certain antibodies or a related blood vessel condition. Seven adults took the drug for a year, and researchers measured changes in lung function and tracked side effects. The goal was to see if the drug could slow or stop the disease from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.